KLRK1 and glioblastoma: The results indicated that VPA-treated glioblastoma cancer cells can stimulate CAR-T to secrete a higher IFN-γ response compared to the untreated groups (Figures 3B, C), further confirming that VPA pretreatment can enhance glioblastoma cell recognition to NKG2D CAR-T mediated immune response.